Respiratory Complications, Vibration
Conditions
Brief summary
A medical professional trained in the procedure and use of the device will conduct the vibroacoustic therapy session. He will also take blood samples. In the control group, patients will undergo vibroacoustic pulmonary therapy in the "Pneumonia" mode, and in the control group, in the "Prevention" mode. Vibroacoustic pulmonary therapy will be conducted over a period of 5 days. A similar algorithm of actions is planned for both groups. VALT sessions will be conducted 4-6 times a day for 5 minutes in combination with treatment according to the protocol for the use of "Vibroacoustic Therapy" of the lungs of the Ministry of Health of the Republic of Kazakhstan. The device's emitters will be applied to the affected areas of the lungs. Since the device has long cords for the emitters and is portable, it is not difficult to change the patient's position and does not require their active participation, which is important for patients on ventilators and with limited mobility.
Interventions
DEVICEVibrolung
BARK VibroLUNG vibroacoustic device (No. RK-MT-7No.013611 dated October 7, 2014). The device is designed for the treatment and prevention of respiratory diseases. The device operates on the principle of exposure to a powerful vibroacoustic signal generated by special emitters. During the procedure, the emitters are pressed against the surface of the chest, and the procedure lasts an average of 5 minutes. The frequency of the signal constantly changes and has complex modulation, which ensures maximum effectiveness. Depending on the selected program, the signal can cause the effect of percussion, soft vibration, smooth alternation of acoustic signal and vibration, or combinations thereof.
Sponsors
Astana Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Intervention model description
The device generates electrical signals that are converted into high-intensity acoustic waves by two vibroacoustic emitters. The emitters are applied to the surface of the chest, and the sound waves propagate to the lungs, causing vibrations in the structures of the lung parenchyma. The frequency of the exposure signal constantly changes, which provides a number of effects, including the resonance effect.
Eligibility
Sex/Gender
ALL
Age
60 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* respiratory failure; * hip fracture; * Injury Severity Score no higher than 8 points.
Exclusion criteria
* All contraindications for use of the device: * terminal condition of the patient; * shock; * paradoxical pathological breathing; * hypertensive crisis; * severe hypocoagulation with a risk of hematoma formation or bleeding in the projection of exposure; * severe hypercoagulation, risk of thrombus/embolus migration along the main vessels in the area of exposure; * acute cerebrovascular accident in the first 1-3 days; * brain edema; * presence of multiple purulent or burn wound surfaces in the area of exposure; * presence of unstable rib fractures; * pneumomediastinum and/or subcutaneous emphysema of the chest; * osteomyelitis of the ribs and/or thoracic spine; * spinal fracture without orthopedic fixation; * chest or abdominal trauma with bleeding; * Injury Severity Score greater than 8 points; * concomitant diseases in the stage of decompensation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Arterial blood gases | Day 1 | On day 1 of vibroacoustic therapy, arterial blood sampling will be performed to determine PaO2 (mmHg), PaC02 (mmHg), as well as for dynamics during transfer to the specialized department. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Chest X-ray | Day 1 | Chest X-ray at admission and after vibroacoustic therapy sessions at least twice in total, with technical capabilities(The X-ray image) |
Countries
Kazakhstan
Contacts
CONTACTAssema Bekniyazova
Outcome results
None listed